JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients

Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disorder with a heterogeneous clinical presentation and the cardinal symptom of itch, that results in significant patient burden and a significant decrease in patient’s quality of life.1 The pathogenesis of AD is multifactorial and results from an immune response skewed toward the Th2 axis, displaying upregulation of key cytokines, including interleukin 4 (IL-4), IL-5, IL-13, and IL-31.2,3 Dupilumab, a biologic, which inhibits IL-4 and IL-13 signaling via the inhibition of the IL-4 receptor alpha subunit, was the first targeted treatment approved for AD.